Valuation Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE
Stocks
PLX
US74365A3095
Pharmaceuticals
|
Delayed
TEL AVIV STOCK EXCHANGE
18:24:48 21/03/2023 +03
|
5-day change | 1st Jan Change | ||
| 732.50 ILa | -.--% |
|
+3.29% | +69.68% |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 222.4 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 53.62% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 222.4 | 222.4 | 222.4 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 53.62% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 11.5x | 55.2x | 138x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.7x | -2.3x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.71x | 3.35x | 3.23x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.71x | 3.35x | 3.23x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 9.84x | 85.9x | 197x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.24 | 0.05 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 82.16 | 66.48 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 22.59 | 2.588 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 19.63 | 3.794 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.760 | 2.760 | 2.760 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 3/31/22 A | 2/27/23 A | 3/14/24 A | 3/17/25 A | 3/18/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.9x | 11.93x | 24.23x | 0.6% | 1,031B | |
| 29.45x | 6.54x | 18.31x | 2.02% | 638B | |
| 33.1x | 7.75x | 16.02x | 2.65% | 462B | |
| 105.72x | 5.91x | 25.05x | 2.35% | 359B | |
| 19x | 4.63x | 11.48x | 2.87% | 335B | |
| 20.37x | 5.28x | 13.08x | 3.03% | 273B | |
| 20.79x | 4.31x | 12.28x | 2.05% | 253B | |
| 26.62x | 6.92x | 12.32x | 2.39% | 228B | |
| -45.08x | 6.57x | 25.65x | 2.21% | 185B | |
| Average | 26.98x | 6.65x | 17.60x | 2.24% | 418.21B | |
| Weighted average by Cap. | 32.10x | 7.72x | 18.90x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
